Published in

Elsevier, Lancet Haematology, 11(7), p. e798-e807, 2020

DOI: 10.1016/s2352-3026(20)30291-x

Links

Tools

Export citation

Search in Google Scholar

Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group

Journal article published in 2020 by Steven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, Victoria Cacheux, Violaine Safar, Barbara Burroni, Stéphanie Guidez, Thomas Gastinne, Danielle Canioni, Catherine Thieblemont, Hervé Maisonneuve, Caroline Bodet-Milin, Roch Houot, Lucie Oberic, Krimo Bouabdallah and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO